What’s Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Read original at benzingaStocks · News reference
Needham Maintains Buy on Personalis, Raises Price Target to $17
Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $12 to $17.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 17, 2026, 10:43 AM
- Checked
- Jul 17, 2026, 10:43 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
On Aug 20, Personalis Received A New Task Order Under Its Contract With U.S. Department Of Veterans Affairs For VA MVP; New Task Order Effective Sept 30, 2026, Valued Up To $18.30M
On August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order is effective on
Read original at benzinga8-K filing — Personalis, Inc. (PSNL)
Filed: 2026-08-20 AccNo: 0001193125-26-359300 Size: 156 KB Item 8.01: Other Events
Read original at edgarModerna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today
Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as gold soars.
Read original at benzinga